[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# GSK plc (GSK)

GSK plc's stock price is near a 52-week high, with recent social media buzz around FDA approvals and financial performance. However, concerns linger over Blenrep's label restrictions and pipeline challenges.

### About GSK plc
GSK plc is a multinational pharmaceutical and biotechnology company.  
GSK plc uses the ticker $GSK for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- GSK plc (GSK) trading volume is up XXXXX% from the previous week.
- GSK plc (GSK) social dominance is up XXXXXX% from the previous week.
- GSK plc (GSK) posts created is up XXXXX% from the previous week.
- GSK plc Price hit a 52-Week high of $XXXXX for the hour
- GSK plc Price hit an all time of $XXXXX for the hour

### Price: $XXXXX
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/close.tsv)  
GSK's stock price is near a 52-week high, supported by positive sentiment from FDA approvals and social media engagement, but recent legal disputes and concerns over Blenrep's label restrictions may introduce volatility.  

24-Hour: -XXXX%
7-Day: XXXX%
30-Day: -XXXX%

1-Year High: $XX on 2025-12-03  
1-Year Low: $XXXXX on 2025-01-14  
  
  
### AltRank: XXXXX
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/alt_rank.tsv)  
GSK plc (GSK) is currently AltRank #1,183 based on combined combined social and market metrics
Daily Average: XXX  
X Week: XXXXX +415  
X Month: XXXXX +226  
X Months: XXXXX +1,056  
X Year: XXXXX +587  
1-Year High: XXXXX on 2025-06-19  
1-Year Low: X on 2025-02-09  
  
  
### Galaxy Score: XXXXX
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/galaxy_score.tsv)  
Current Value: XXXXX  
Daily Average: XX  
X Week: XX -XX  
X Month: XX -XX  
X Months: XX -XX  
X Year: XX -XX  
1-Year High: XX on 2025-05-13  
1-Year Low: XX on 2025-07-03  
  
  
### Engagements: XXXXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/interactions.tsv)  
Current Value: XXXXX  
Daily Average: XXXXXX  
X Week: XXXXXX -XX%  
X Month: XXXXXXX -XX%  
X Months: XXXXXXXXX +29%  
X Year: XXXXXXXXX -XX%  
1-Year High: XXXXXXX on 2025-02-05  
1-Year Low: XXX on 2025-12-07  

Engagements by network (24h):
Reddit: XX
X: XXXXX
YouTube: XX

  
  
### Mentions: XX (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/posts_active.tsv)  
Current Value: XX  
Daily Average: XXX  
X Week: XXX -XX%  
X Month: XXX -XX%  
X Months: XXXXX +72%  
X Year: XXXXX +73%  
1-Year High: XXX on 2025-08-03  
1-Year Low: XX on 2025-12-07  

Mentions by network (24h):
Reddit: X
X: XXX
YouTube: X

  
  
### Creators: XX (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/contributors_active.tsv)  
XX unique social accounts have posts mentioning GSK plc (GSK) in the last XX hours which is down XX% from XX in the previous XX hours
Daily Average: XX  
X Week: XX -XX%  
X Month: XXX -XX%  
X Months: XXXXX +72%  
X Year: XXXXX +65%  
1-Year High: XXX on 2025-06-28  
1-Year Low: XX on 2025-12-07  

The most influential creators that mention GSK plc in the last XX hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@BiopharmIQ](/creator/twitter/BiopharmIQ)           | X    | XXXXXX    | X     | XXX         |
| [@MoneyMaker0009](/creator/twitter/MoneyMaker0009)   | X    | XXX       | X     | XXX         |
| [@doepke_michel](/creator/twitter/doepke_michel)     | X    | XXXXX     | X     | XX          |
| [@semodough](/creator/twitter/semodough)             | X    | XXXXXX    | X     | XX          |
| [@Darwin_Knows](/creator/twitter/Darwin_Knows)       | X    | XXX       | X     | XX          |
| [@StableBread](/creator/twitter/StableBread)         | X    | XXXXX     | X     | XX          |
| [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) | X    | XXXXX     | X     | XX          |
| [@StockMKTNewz](/creator/twitter/StockMKTNewz)       | X    | XXXXXXX   | X     | XX          |

[View More](/list/creators/gsk-plc/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/sentiment.tsv)  
Current Value: XXX%  
Daily Average: XX%  
X Week: XXX% no change  
X Month: XXX% +17%  
X Months: XXX% +5%  
X Year: XXX% +27%  
1-Year High: XXX% on 2025-04-21  
1-Year Low: XX% on 2025-08-26  

Most Supportive Themes:
- FDA Approval of Blenrep: (30%) GSK's multiple myeloma drug Blenrep has received FDA approval for specific patient groups, marking a significant regulatory milestone.
- Earnings Reports and Financial Performance: (25%) GSK's recent earnings reports and financial performance are being closely watched and discussed, with revenue and EPS figures highlighted.
- Partnerships and Acquisitions: (20%) GSK is actively engaging in strategic partnerships and acquisitions, such as the deal with Empirico, to expand its pipeline and market reach.
  
Most Critical Themes:
- Blenrep Label Restrictions: (40%) Despite FDA approval, Blenrep's label is narrower than anticipated, raising concerns about its near-term commercial upside and market penetration.
- Pipeline Development Challenges: (35%) GSK faces ongoing challenges in its R&D pipeline, with some drug candidates like the one partnered with Alector failing in late-stage trials.
  
  
  
### Social Dominance: XXXXXXX%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/social_dominance.tsv)  
Current Value: XXXXXXX%  
Daily Average: XXXXX%  
X Week: XXXXXX% +0.0037%  
X Month: XXXXX% +0.0002999999999999999%  
X Months: XXXXX% -XXXXXX%  
X Year: XXXXX% -XXXXX%  
1-Year High: XXXXX% on 2025-01-02  
1-Year Low: XXXXXX% on 2025-12-07  
  
  
### Market Dominance: XXXXX%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/market_dominance.tsv)  
Current Value: XXXXX%  
Daily Average: X%  
1-Year High: XXXX% on 2025-03-31  
1-Year Low: XXXXX% on 2024-12-16  
  
  
### Market Cap: $XXXXXXXXXXXXXX
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:gsk-plc/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/gsk-plc/time-series/market_cap.tsv)  
Current Value: $XXXXXXXXXXXXXX  
Daily Average: $XXXXXXXXXXXXXX  
X Week: $XXXXXXXXXXXXXX -$1.50%  
X Month: $XXXXXXXXXXXXXX +$1.90%  
X Months: $XXXXXXXXXXXXXX +$11%  
X Year: $XXXXXXXXXXXXXX +$30%  
1-Year High: $XXXXXXXXXXXXXX on 2025-12-03  
1-Year Low: $XXXXXXXXXXXXXX on 2025-01-14  

### Top GSK plc Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"BREAKING: Novartis ($NVS) just signed a massive $1.75B deal with Relation Therapeutics to hunt for new dermatology targets. The "Alpha" isn't just the dollar figureit's the technology. Relation uses a "Lab-in-the-Loop" AI platform and is backed by Nvidia ($NVDA) and $GSK. Big Pharma is officially paying a premium to outsource discovery to the AI-native biotechs. Deal terms: $55M Upfront / $1.7B Milestones. $NVS $NVDA $GSK $XBI $IBB"  
[X Link](https://x.com/BioSignal/status/1998581189754630327) [@BioSignal](/creator/x/BioSignal) 2025-12-10T02:31Z XX followers, XX engagements


"FTSE100 Fallers: Diageo PLC (#DGE) -XXXX% Tesco PLC (#TSCO) -XXXX% GSK PLC (#GSK) -XXXX% Next PLC (#NXT) -XXXX% Intertek Group PLC (#ITRK) -1.9%"  
[X Link](https://x.com/therealmccoys__/status/1998445580465422711) [@therealmccoys__](/creator/x/therealmccoys__) 2025-12-09T17:32Z 1301 followers, XXX engagements


"$HIRU - Ameerex Advances Corcoran Canyon Silver-Gold Acquisition and Prioritizes Producing Oil Assets With Offer for 5200 BOE/Day Canadian Field $PG $MRK $MYL $VRTX $BIIB $BMY $JNJ $AZN $REGN $JNJ $PFE $GSK $LLY $ABT $SNY $NVO $NVS $WBA $RAD $HLF"  
[X Link](https://x.com/WallstUpdate25/status/1998424742416777330) [@WallstUpdate25](/creator/x/WallstUpdate25) 2025-12-09T16:09Z XX followers, XXX engagements


"$APAAF - Appia Announces Drilling Updates on ULTRA HARD ROCK Target and Auger Drilling on ULTRA IAC Target in Goias $PG $MRK $MYL $VRTX $BIIB $BMY $JNJ $AZN $REGN $JNJ $PFE $GSK $LLY $ABT $SNY $NVO $NVS $WBA $RAD $HLF $CJJD $GNC $DPLO $IPXL $TSCO"  
[X Link](https://x.com/MoneyMaker0009/status/1998419707691708575) [@MoneyMaker0009](/creator/x/MoneyMaker0009) 2025-12-09T15:49Z XXX followers, XX engagements